FDA issues final guidance on cIAI antibiotics

FDA issued (see BioCentury Extra, Sept. 28, 2012).

The updated guidance clarifies the primary efficacy endpoint of clinical success, which is defined as the resolution of baseline signs and symptoms attributable to cIAI 28 days after treatment start. ...